日韩精品久久一区二区三区_亚洲色图p_亚洲综合在线最大成人_国产中出在线观看_日韩免费_亚洲综合在线一区

Global EditionASIA 中文雙語Fran?ais
China
Home / China / Health

Approval sped up for pediatric drugs

By WANG XIAOYU | China Daily | Updated: 2022-06-02 09:19
Share
Share - WeChat
[Photo/VCG]

China's top drug regulator has sped up approval for pediatric medications in recent years, the National Medical Products Administration said on Tuesday.

The administration has granted pediatric urgently-needed drugs priority when it comes to reviews, and has set up green channels and designated personnel to supervise approval procedures to reduce review times as much as possible.

The development of pediatric drugs is even more contentious and time-consuming than that of drugs for adults due to obstacles and uncertainties associated with rolling out clinical trials or devising dosages.

Last year, 47 pediatric drugs or medications previously not eligible for children's use were granted market approval, among them inhalants, rotavirus vaccines and traditional Chinese medicines.

"The number of newly approved drugs was far higher than the previous year," the administration said, adding that the number of applications and approvals for pediatric drugs has been trending upward in recent years.

Between January and April, the administration completed 30 approval procedures for 21 pediatric drugs, eight of which had qualified for priority review.

"The completed workload for pediatric drug evaluation increased by 90.91 percent over the same period last year," the administration said.

In the meantime, it has been importing new pediatric drugs in urgent demand.

Some of the newly approved products include an infusion for spinal muscular atrophy and another for treating Fabry disease, a rare genetic condition that causes a buildup of fats in the bloodstream.

On May 21, a 10-year-old girl in Chongqing received Replagal, the drug for treating Fabry disease, at the Children's Hospital of Chongqing Medical University.

The drug was selected for a list of medications qualified for expedited review and approval in 2018 and granted market approval in China in August, 2020. In October last year, the medication was added onto the national drug reimbursement list.

Wang Mo, head of the nephrology department at the hospital, said during an interview with People's Daily that each round of treatment required two injections, which would have cost 6,000 yuan ($896).

With reimbursement, the girl's family only needed to cover less than 3,000 yuan, she said.

Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
 
主站蜘蛛池模板: 91精品国产欧美一区二区 | 国产精品久久久久久 | 日本激情视频一区二区三区 | 亚洲欧美综合乱码精品成人网 | 精品国产不卡一区二区三区 | 日本九九视频 | 国产精品视频免费观看 | 日韩精品一区二区三区中文字幕 | 99热久久这里只精品国产 | 欧美三级 在线播放 | 久久综合九色综合97婷婷群聊 | 夜夜操网 | 国产精品美女久久久久久 | 免费一级在线 | 久草中文在线 | 天天爽天天碰狠狠添 | 久久久久久久久久综合情日本 | 国产精品久久久久久久久久iiiii | 九一免费在线观看 | 欧美日韩精 | 国产综合精品 | 亚洲宗合| 国产精品美女久久久久久久久久久 | www.久草.com | 欧美性生活区 | 魏千翔 | 99久久婷婷| 色婷婷色 | 国产综合av | 日韩av免费在线观看 | 亚洲精品1 | 日韩精品一区二区三区中文在线 | 99久久久精品 | www久久av | 成人免费影 | 中文字幕在线二区 | 婷婷激情久久 | 日本精品一区二区三区四区 | 青青久久久国产线免观 | 日韩精品久 | 欧美激情一区二区三区视频高清 |